tapebrief
IFF · Q2 2025

IFF · Q3 2025 Earnings

Cautious

International Flavors & Fragrances

Reported November 4, 2025

30-second summary

Comparable currency-neutral sales were flat (0%) in Q3, landing as management telegraphed against the toughest 2024 comp, while CN EBITDA grew 7% and the full-year guide was reaffirmed across all four metrics. Headline revenue fell 8% YoY to $2.69B (Pharma divestiture cycling), adjusted EBITDA margin held at 19.3%, and leverage stayed at 2.5x. The notable concession: management now expects FY CN sales at the low end of the 1-4% range and FY EBITDA near the midpoint of 5-10%, and the CEO explicitly flagged Q4 as "a challenge" with improvement deferred to 2026 — a tone walk that continues the defensive pivot from Q2.

Headline numbers

EPS

Q3 FY2025

$1.05

Revenue

Q3 FY2025

$2.69B

-8.0% YoY

Gross margin

Q3 FY2025

36.5%

Operating margin

Q3 FY2025

8.4%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$2.69B-8.0%$2.76B-2.5%
EPS$1.05—$1.15-8.7%
Gross margin36.5%—37.3%-80bps
Operating margin8.4%—7.2%+120bps

Guidance

Company reaffirmed full year 2025 financial guidance across all metrics; Q3 FY2025 delivered results broadly in line with prior expectations of growth moderation.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Comparable Currency Neutral Sales GrowthQ3 FY2025Growth to moderate in Q3, particularly due to strong year-over-year comparison0%in-line with moderation expectationMet

New guidance

MetricPeriodGuideYoY
Comparable Currency Neutral Adjusted Operating EBITDA GrowthQ3 FY20257%—

Reaffirmed unchanged this quarter: Comparable Currency Neutral Sales Growth (1% to 4% (expecting low end)), Comparable Currency Neutral Adjusted Operating EBITDA Growth (5% to 10% (expecting near mid-point)), Adjusted Operating EBITDA ($2.0 billion to $2.15 billion), Revenue ($10.6 billion to $10.9 billion)

Segment KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
Taste$0.635B+2.0%
Food Ingredients$0.83B-2.0%
Health & Biosciences$0.577B+2.0%
Scent$0.652B+6.0%
Taste Adjusted Operating EBITDA Margin20.2%—
Food Ingredients Adjusted Operating EBITDA Margin12.8%—
Health & Biosciences Adjusted Operating EBITDA Margin26.0%—
Scent Adjusted Operating EBITDA Margin20.7%—

Other KPIs

Q3 FY2025
SegmentQ3 FY2025
Adjusted Operating EBITDA Margin19.3%
Comparable Currency Neutral Sales Growth0%
Comparable Currency Neutral Adjusted Operating EBITDA Growth7%
Net Debt to Credit Adjusted EBITDA2.5x

Management tone

Q2 inflection deferred to 2026 → Q3 execution-only narrative with Q4 flagged as another challenge.

The narrative has formally shifted from growth to execution and margin defense. Last quarter management framed 2025 as a transition year with R&D investments ramping into 2026 and full benefit in 2027; this quarter the CEO's anchor line is "In a more challenging environment, we are doing what we said we would do." That is not the language of a company driving momentum — it's the language of a company managing expectations down and reframing reaffirmed guidance as the achievement. Two quarters ago the discussion centered on the innovation pipeline; this quarter it centers on whether the FY ranges hold.

Q4 has now been explicitly tagged as a challenge — a step down from Q2's "Q3 is the hardest comp" framing. In Q2 management positioned Q3 as the toughest quarter against 2024 comps and implied recovery thereafter. This quarter the CEO said "while the fourth quarter will remain a challenge, we expect trends to improve in 2026" — pushing the recovery thesis another quarter out. The Q4 comparable is now 6% (per Q&A) versus Q3's 9%, so the comp gets easier, but management is still cautious. That gap between easier-comp and cautious-guide is the tone tell.

Profitability has replaced growth as the primary value driver in management's own framing. Q2's "Food Ingredients +21% CN EBITDA growth" was celebrated as evidence of the operational engine. This quarter the CEO said "Our focus on profitability continues to bear fruit as our results demonstrated strong profitability even in this lower growth environment" — the phrase "lower growth environment" is new and conceptual; management is acknowledging a regime change, not a transient slowdown. The +7% CN EBITDA on flat CN sales is the proof point being highlighted.

Food Ingredients strategic review remains the open question, with no defined process. Q2 management said "absolute clarity in 2026" and flagged proactive PE/strategic interest. This quarter: "we are making very good progress, generating significant interest" — language that has marginally advanced but still no defined sale-vs-spin announcement, no value framework, no timeline beyond the Q4 February call. For a process flagged 6+ months ago, this is slower than the Q2 framing implied.

Hedging language density has increased materially. "We expect to deliver financial results in line with our full year guidance," "we expect trends to improve in 2026," "subject to how we see things today and contain elements of uncertainty" — five distinct hedges flagged in this print versus a narrower set in Q2. The cumulative effect is a management team that has moved from conditional optimism to conditional execution.

Recurring themes management leaned on this quarter:

Macro headwinds and market uncertainty constraining growthMargin expansion and profitability as primary focus in challenging environmentPortfolio optimization and divestitures driving margin enhancementStrategic innovation investments with delayed monetization (mid-late 2026+)Operational discipline and execution against guidanceBalance sheet strength and deleveraging achievement enabling capital flexibility

Risks management surfaced:

Ongoing macro headwinds and geopolitical challengesMarket uncertainty influencing customers and end consumersH&B North America health business weakness persisting into Q4Strong year-ago comparables creating headwinds (9% in Q3, 12% in taste for Q4)Food ingredients business under strategic review with execution risk

Q&A highlights

Nicole Lateng · BNP Carabas

Asked about Q4 top-line guidance implying negative low single-digit growth despite easier comps, seeking clarification on macro versus IFF-specific headwinds and what end-market recovery is needed for 2026 acceleration.

Management attributed cautious Q4 outlook primarily to macro environment with soft volume demand in food and beverage and HPC categories. Noted fragrance ingredients and health North America as focus areas representing ~5% of sales. Expressed cautious optimism for 2026 growth acceleration as markets normalize and self-help initiatives yield results.

Q4 comparable is 6% (down from 9% in Q3)Food and veg category and HPC showing soft volume demandFragrance ingredients and health North America represent ~5% of total company salesCautiously optimistic on 2026 growth acceleration pending market normalization

Lisa Denise · Morgan Stanley

Asked for free cash flow outlook for 2025 and component breakdown, plus details on health and biosciences investments including any new plant openings.

2025 free cash flow expected modestly below $500 million target due to higher inventories (strategic stock build) and elevated one-time costs from portfolio work, partially offset by lower CapEx. Fourth quarter expected to show improvement in working capital. On H&B, management highlighted increased R&D and commercial capability spending, and confirmed AlphaBio DEB plant construction on track for 2027 startup.

2025 free cash flow guidance: modestly below $500 million targetCapEx expected lower than plannedHigher inventories due to strategic stock building in key areasElevated Reg G and one-time costs from portfolio work

Salvatore Tiano · Bank of America

Asked about discrete items affecting income statement and cash flow in 2026 versus 2025.

Management noted one key discrete item: the pharma transaction divestiture (closed May 1st) which contributed ~$369 million in sales and $76 million EBITDA for ~4-5 months of 2025, will fully cycle out in first half of 2026. No other material discrete items flagged; remainder of 2026 expected to be normal course operations.

Pharma transaction closed May 1st, 2025Pharma business contributed ~$369 million sales and ~$76 million EBITDA for 4-5 months in 2025Pharma will cycle out fully in first half of 2026No other major discrete items flagged for 2026

Josh Spector · UBS

Asked about ability to deliver earnings growth higher than 1% revenue growth in 2026 if macro stays weak, and what self-help levers are available.

Management acknowledged growth is important for fixed cost leverage but confirmed contingency planning for 1-2% growth environment. Cost structure improvement is paramount, with focus on streamlining corporate functions, leveraging automation, and redesigning processes. Acknowledged productivity opportunities exist to maximize profitability in lower growth scenarios.

Cost optimization focus includes streamlining corporate functions, leveraging automation, redesigning processesContingency planning in place for 1-2% growth environmentTeam has driven productivity improvement over last couple of yearsAdditional opportunities for incremental productivity identified

Fulvio Casal · Barenburg

Asked for color on health business weakness in North America, whether Q3 decline was anticipated, and if 2026 improvement timeline is still on track or if there's increased uncertainty.

Management confirmed North America health business has been slow; responded by placing new leadership with strong commercial/marketing capabilities, step-changing innovation pipeline investment, and connecting with existing and new customers. Expects improvements particularly in H2 2026 going into 2027, with full recovery and return to growth trajectory in 2027.

New leadership installed in health North America with strong commercial and marketing capabilitySignificant innovation pipeline investment made (step-change from prior year)Focus on customer growth acceleration and new customer acquisitionExpected improvements in H2 2026 going into 2027

Answers to last quarter's watch list

Q3 FY2025 currency-neutral growth print — CN sales came in at 0% — at the low end of management's "growth will moderate" framing but not negative. Above the sub-1% red line that would have put the FY range in jeopardy, but barely. Reported sales -8% YoY reflects pharma divestiture.
Continue monitoring
Food Ingredients strategic alternatives update — No defined process announced. Management said "making very good progress, generating significant interest" but deferred specifics to the February Q4 call. No transaction value framework, no sale-vs-spin decision disclosed.
Continue monitoring
Fragrance ingredients trajectory — Management flagged fragrance ingredients (alongside health North America) as ~5% of total sales and the specific focus areas for Q4 weakness; no quantified evidence the segment is flattening yet. The Q2 thesis (negative H2, flat 2026, growth 2027) is intact in narrative but not yet confirmed in print.
Continue monitoring
H&B capacity utilization commentary — AlphaBio DEB plant confirmed on track for 2027 startup with Kemira JV; H&B segment delivered +2% reported sales and 26.0% EBITDA margin. No specific utilization metrics disclosed.
Not resolved
Net leverage and buyback pacing — Leverage held at 2.5x net debt / credit-adjusted EBITDA. FY25 FCF guided "modestly below" the $500M target due to strategic inventory build and one-time portfolio costs. No specific repurchase pace disclosed on the print.
Continue monitoring

What to watch into next quarter

Q4 FY2025 CN sales growth vs. the 6% PY comp — management has explicitly flagged Q4 as a challenge despite the easier comp; watch whether CN sales hold positive. A negative Q4 print would force the FY range below its low end, breaking the all-year reaffirmation.

Food Ingredients strategic alternatives at the February Q4 call — management has committed to providing more clarity. A defined process announcement (sale vs. spin, timeline, value framework) is the binary catalyst; further deferral would be a negative signal given 6+ months of "significant interest" commentary.

Initial 2026 guide framing — particularly whether management can deliver EBITDA growth that exceeds revenue growth in a 1-2% sales environment, and how the pharma divestiture (~$369M sales, ~$76M EBITDA) cycling out is bridged. The Q&A confirmed a defensive playbook exists; the February call must quantify it.

FCF generation in Q4 and the $500M target gap — management guided modestly below $500M; watch the actual landing and the working capital reversal management implied. Sustained FCF underperformance pressures the buyback authorization pacing.

Health North America — first concrete data point on the new leadership and innovation pipeline impact; management framed recovery as H2 2026 / 2027, so Q4 needs to show stabilization, not growth.

Sources

  1. IFF Q3 FY2025 Press Release — https://www.sec.gov/Archives/edgar/data/51253/000005125325000047/q32025991pressreleaseofiff.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.